Want to see SXTP full AI Analyst Report?
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.96
▼(-11.11% Downside)
Action:Reiterated
Date:10/06/26
The score is held down primarily by weak financial performance—very large losses and ongoing cash burn despite revenue growth and no current debt. Technicals are moderately supportive in the near term (price above key moving averages, positive MACD) but are stretched by overbought signals. Corporate events provide potential upside catalysts around tafenoquine/FDA steps, offset by disclosed funding/going-concern and reverse-split related risks, while valuation remains constrained by unprofitability and no indicated dividend support.
Positive Factors
Revenue Growth
Revenue growth indicates that Arakoda is gaining commercial traction in its malaria prophylaxis market. If the company can sustain demand and improve operating leverage, the expanding top line could provide a foundation for funding product development and strengthening its infectious-disease platform.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is not yet self-funding its operations or development programs. Continued cash consumption can restrict investment capacity and leave the company dependent on additional financing before revenue growth becomes sufficient to support the broader strategy.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth indicates that Arakoda is gaining commercial traction in its malaria prophylaxis market. If the company can sustain demand and improve operating leverage, the expanding top line could provide a foundation for funding product development and strengthening its infectious-disease platform.
Read all positive factors
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.40M
Dividend YieldN/A
Average Volume (3M)178.73K
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue Growth24.77%
EPS Growth86.32%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.05
Shares Outstanding3,516,988
10 Day Avg. Volume401,911
30 Day Avg. Volume178,727
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap3.91
Enterprise Value/Revenue11.95
Enterprise Value/Gross Profit61.55
Enterprise Value/Ebitda-1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-3.31
Revenue Forecast (FY)$1.00M
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an ap...
How the Company Makes Money
The company makes money primarily by selling its tafenoquine-based malaria products. Key revenue streams include (1) product sales of Arakoda (tafenoquine) in the United States, generated through distribution to pharmacies/wholesalers and other ch...
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11M | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M |
| Gross Profit | 215.79K | 223.78K | 222.81K | -220.98K | -209.16K | 309.60K |
| EBITDA | -8.01M | -7.28M | -7.88M | -1.43M | -2.11M | -1.01M |
| Net Income | -8.11M | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
Balance Sheet | ||||||
| Total Assets | 4.28M | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02M | 2.75M | 3.39M | 2.14M | 264.87K | 115.40K |
| Total Debt | 151.18K | 152.78K | 155.89K | 172.67K | 22.42M | 18.80M |
| Total Liabilities | 1.75M | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Stockholders Equity | 2.61M | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
Cash Flow | ||||||
| Free Cash Flow | -8.95M | -7.07M | -5.83M | -4.66M | -1.07M | -684.50K |
| Operating Cash Flow | -8.77M | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K |
| Investing Cash Flow | -288.34K | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K |
| Financing Cash Flow | 8.11M | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
1.08
Price Trends
1.09
Negative
1.31
Negative
1.87
Negative
Market Momentum
<0.01
Positive
40.83
Neutral
15.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 1.08 is below the 20-day moving average (MA) of 1.11, below the 50-day MA of 1.09, and below the 200-day MA of 1.87, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 15.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.40M | -0.16 | -211.59% | ― | 24.77% | 86.32% | |
| ― | $2.06M | -0.13 | -144.23% | ― | ― | 86.26% | |
40 Underperform | $5.68M | >-0.01 | -222.32% | ― | ― | 78.25% | |
33 Underperform | $3.25M | -0.07 | -91.95% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
SXTP
60 Degrees Pharmaceuticals, Inc.
0.97
-5.48
-85.02%
OGEN
Oragenics
0.46
-0.83
-64.65%
KALA
KALA BIO
0.29
-74.21
-99.61%
KTTA
Pasithea Therapeutics Corp
0.47
-0.27
-36.89%
SPRC
SciSparc Ltd.
4.47
-26.76
-85.69%
ONCO
Onconetix
0.62
-183.38
-99.66%
60 Degrees Pharmaceuticals, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
60 Degrees highlights interim tafenoquine data, caps enrollment
Positive
Oct 6, 2026
On October 6, 2026, 60 Degrees Pharmaceuticals updated its investor presentation and held a webinar detailing interim data from its study of tafenoquine for severe hospitalized babesiosis, alongside an announced update to its January 2027 data rea...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
60 Degrees Advances Babesiosis Treatment With FDA Submission
Positive
Sep 14, 2026
On September 12, 2026, 60 Degrees Pharmaceuticals submitted a Statement of Interest to the U.S. Food and Drug Administration seeking a Commissioner’s National Priority Voucher for an efficacy supplement to its ARAKODA (tafenoquine) NDA for t...
Business Operations and StrategyFinancial Disclosures
60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases
Negative
Sep 8, 2026
On September 8, 2026, 60 Degrees Pharmaceuticals updated its investor presentation, highlighting a strategy to leverage ARAKODA’s existing malaria prophylaxis label and commercial footprint into potential new indications for babesiosis and o...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions
Positive
Aug 6, 2026
On August 5, 2026, 60 Degrees Pharmaceuticals, Inc. held its virtual 2026 annual stockholders meeting, with about 41.6% of outstanding voting shares represented, and shareholders elected five directors to serve until the 2027 meeting while ratifyi...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
Neutral
Aug 4, 2026
On July 30, 2026, 60 Degrees Pharmaceuticals entered into definitive securities purchase agreements with institutional investors for a private placement of common stock or pre-funded warrants, along with Series A and short-term Series B warrants, ...
Business Operations and StrategyRegulatory Filings and Compliance
60 Degrees updates strategy for ARAKODA and profitability
Neutral
Jul 20, 2026
On July 20, 2026, 60 Degrees Pharmaceuticals updated its investor presentation for ongoing use with the investment community, outlining its strategy around ARAKODA and broader vector-borne disease programs. The materials highlighted the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.